Breast Cancer: Focus on CDK4&6 Inhibitors

Rationale For CDK4&6 Inhibition in Breast Cancer

December 19, 2017

Clinical Articles

The second most common cancer worldwide, breast cancer remains a significant global burden despite decreased incidence in Western countries. Breast cancer is the fifth leading cause of cancer death in the United States, with more than 40,000 estimated deaths in 2017.

Approved CDK4&6 Inhibitors in Breast Cancer

December 19, 2017

Clinical Articles

The development of CDK4&6 inhibitors has provided promising data regarding this new therapeutic option for patients with cancer, particularly for patients with breast cancer. Currently, there are 3 FDA-approved CDK4&6 inhibitors for the treatment of patients with breast cancer.

Ongoing Trials in Other Settings for CDK4&6 Inhibitors in Breast Cancer

December 19, 2017

Clinical Articles

Prospects for patients with breast cancer have improved with the use of CDK4&6 inhibitors, including palbociclib, ribociclib, and abemaciclib; however, the effects of these inhibitors in many subsets of patients have not been investigated.